178 related articles for article (PubMed ID: 26552221)
21. Role of epithelial mesenchymal transition in prostate tumorigenesis.
Khan MI; Hamid A; Adhami VM; Lall RK; Mukhtar H
Curr Pharm Des; 2015; 21(10):1240-8. PubMed ID: 25506896
[TBL] [Abstract][Full Text] [Related]
22. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma.
Jayachandran A; Dhungel B; Steel JC
J Hematol Oncol; 2016 Aug; 9(1):74. PubMed ID: 27578206
[TBL] [Abstract][Full Text] [Related]
23. [Basal-luminal epithelial cell differentiation in prostate cancer is associated with epithelial-mesenchymal transition and epithelium migration in the mesenchyme].
Korshak OV; Sushilova EN; Voskresenskii MA; Grozov RV; Komyakov BK; Zarytskey AY; Popov BV
Urologiia; 2016 Nov; (5):85-91. PubMed ID: 28248026
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-mesenchymal transition in prostate cancer: an overview.
Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Di Franco R; La Mantia E; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G
Oncotarget; 2017 May; 8(21):35376-35389. PubMed ID: 28430640
[TBL] [Abstract][Full Text] [Related]
25. Cells susceptible to epithelial-mesenchymal transition are enriched in stem-like side population cells from prostate cancer.
Luo Y; Cui X; Zhao J; Han Y; Li M; Lin Y; Jiang Y; Lan L
Oncol Rep; 2014 Feb; 31(2):874-84. PubMed ID: 24316717
[TBL] [Abstract][Full Text] [Related]
26. Generation of In Vitro Model of Epithelial Mesenchymal Transition (EMT) Via the Expression of a Cytoplasmic Mutant Form of Promylocytic Leukemia Protein (PML).
Di Biase A; Miles AK; Regad T
Methods Mol Biol; 2018; 1692():129-138. PubMed ID: 28986893
[TBL] [Abstract][Full Text] [Related]
27. Stabilization of Snail through AKT/GSK-3β signaling pathway is required for TNF-α-induced epithelial-mesenchymal transition in prostate cancer PC3 cells.
Wang H; Fang R; Wang XF; Zhang F; Chen DY; Zhou B; Wang HS; Cai SH; Du J
Eur J Pharmacol; 2013 Aug; 714(1-3):48-55. PubMed ID: 23769744
[TBL] [Abstract][Full Text] [Related]
28. The role of EMT and MET in cancer dissemination.
Banyard J; Bielenberg DR
Connect Tissue Res; 2015; 56(5):403-13. PubMed ID: 26291767
[TBL] [Abstract][Full Text] [Related]
29. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis.
Lee E; Wang J; Yumoto K; Jung Y; Cackowski FC; Decker AM; Li Y; Franceschi RT; Pienta KJ; Taichman RS
Neoplasia; 2016 Sep; 18(9):553-66. PubMed ID: 27659015
[TBL] [Abstract][Full Text] [Related]
30. Elf5 inhibits TGF-β-driven epithelial-mesenchymal transition in prostate cancer by repressing SMAD3 activation.
Yao B; Zhao J; Li Y; Li H; Hu Z; Pan P; Zhang Y; Du E; Liu R; Xu Y
Prostate; 2015 Jun; 75(8):872-82. PubMed ID: 25728398
[TBL] [Abstract][Full Text] [Related]
31. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.
Yamamichi F; Shigemura K; Behnsawy HM; Meligy FY; Huang WC; Li X; Yamanaka K; Hanioka K; Miyake H; Tanaka K; Kawabata M; Shirakawa T; Fujisawa M
Scand J Urol; 2014 Dec; 48(6):523-32. PubMed ID: 25356787
[TBL] [Abstract][Full Text] [Related]
32. Epithelial-mesenchymal transition in breast cancer progression and metastasis.
Wang Y; Zhou BP
Chin J Cancer; 2011 Sep; 30(9):603-11. PubMed ID: 21880181
[TBL] [Abstract][Full Text] [Related]
33. EMT: Mechanisms and therapeutic implications.
Singh M; Yelle N; Venugopal C; Singh SK
Pharmacol Ther; 2018 Feb; 182():80-94. PubMed ID: 28834698
[TBL] [Abstract][Full Text] [Related]
34. Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.
Slabáková E; Kharaishvili G; Smějová M; Pernicová Z; Suchánková T; Remšík J; Lerch S; Straková N; Bouchal J; Král M; Culig Z; Kozubík A; Souček K
Oncotarget; 2015 Nov; 6(34):36156-71. PubMed ID: 26416355
[TBL] [Abstract][Full Text] [Related]
35. Involvement of partial EMT in cancer progression.
Saitoh M
J Biochem; 2018 Oct; 164(4):257-264. PubMed ID: 29726955
[TBL] [Abstract][Full Text] [Related]
36. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance.
Liu CH; Tang WC; Sia P; Huang CC; Yang PM; Wu MH; Lai IL; Lee KH
Int J Med Sci; 2015; 12(1):63-71. PubMed ID: 25552920
[TBL] [Abstract][Full Text] [Related]
37. Aberrant cancer metabolism in epithelial-mesenchymal transition and cancer metastasis: Mechanisms in cancer progression.
Huang R; Zong X
Crit Rev Oncol Hematol; 2017 Jul; 115():13-22. PubMed ID: 28602165
[TBL] [Abstract][Full Text] [Related]
38. The metastasis suppressor CD82/KAI1 inhibits fibronectin adhesion-induced epithelial-to-mesenchymal transition in prostate cancer cells by repressing the associated integrin signaling.
Lee J; Byun HJ; Lee MS; Jin YJ; Jeoung D; Kim YM; Lee H
Oncotarget; 2017 Jan; 8(1):1641-1654. PubMed ID: 27926483
[TBL] [Abstract][Full Text] [Related]
39. Linkage between Twist1 and Bmi1: molecular mechanism of cancer metastasis/stemness and clinical implications.
Wu CY; Hung JJ; Wu KJ
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):668-73. PubMed ID: 21883379
[TBL] [Abstract][Full Text] [Related]
40. Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure.
Verdone JE; Parsana P; Veltri RW; Pienta KJ
Prostate; 2015 Feb; 75(2):218-24. PubMed ID: 25327565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]